{"id":31988,"date":"2021-09-01T01:18:46","date_gmt":"2021-09-01T01:18:46","guid":{"rendered":"https:\/\/dailyhomeland.com\/?p=31988"},"modified":"2021-09-01T01:18:46","modified_gmt":"2021-09-01T01:18:46","slug":"glaxosmithkline-sk-bioscience-start-final-trial-of-covid-19-jab","status":"publish","type":"post","link":"https:\/\/dailyhomeland.com\/?p=31988","title":{"rendered":"GlaxoSmithKline, SK Bioscience start final trial of COVID-19 Jab"},"content":{"rendered":"<p>British drugs giant GlaxoSmithKline and South Korean peer SK bioscience have begun final stage trials of a Covid-19 jab after positive early results, they announced Tuesday.<\/p>\n<p>The vaccine is facing a Phase 3 clinical trial to assess its &#8220;safety and immunogenicity&#8221; when compared with AstraZeneca&#8217;s Covid vaccine, the two companies said in a joint statement.<\/p>\n<p>GSK is still trailing in the wake of Anglo-Swedish rival AstraZeneca, which rapidly developed a successful jab alongside Oxford University despite having little prior experience in vaccine development.<\/p>\n<p>The new jab combines SK bioscience&#8217;s Covid vaccine candidate GBP510 with Glaxo&#8217;s pandemic adjuvant that bolsters the immune response.<\/p>\n<p>&#8220;The advance to Phase 3 study follows positive interim Phase 1\/2 data which showed that all participants who received the adjuvanted vaccine candidate developed strong neutralising antibody responses,&#8221; the pair said Tuesday.<\/p>\n<p>Those responses demonstrated a rate of seroconversion &#8212; or production of antibodies &#8212; of 100 percent, they added.<\/p>\n<p>No safety concerns have so far been identified in the study.<\/p>\n<p>The vaccine is then expected to be supplied via COVAX &#8212; the distributor backed by the World Health Organization and the Gavi vaccine alliance &#8212; subject to positive results and regulatory approvals.<\/p>\n<p>&#8220;While many countries have made good progress with vaccination, there remains a need for accessible and affordable COVID-19 vaccines to ensure equitable access and to protect people across the world,&#8221; said GSK chief global health officer Thomas Breuer.<\/p>\n<p>&#8220;We are pleased to contribute with GSK&#8217;s pandemic adjuvant and to be working with SK to deliver the vaccine at scale via COVAX if it is approved.&#8221;<\/p>\n<p>Results from the Phase 3 trial, which will enrol 4,000 participants from various nations, are expected in the first half of next year.<\/p>\n<p>This will be the first Phase 3 study to compare outcomes of two different Covid-19 vaccine candidates.<\/p>\n<p>SK has received funding from the Coalition for Epidemic Preparedness Initiative and the Bill &amp; Melinda Gates Foundation to help it develop a low-cost jab.<\/p>\n<p>&#8220;Taking this important step towards overcoming the global pandemic situation, SK and GSK will bring our technical expertise together for the development of an adjuvanted protein-based vaccine candidate, GBP510,&#8221; noted SK chief executive Jaeyong Ahn.<\/p>\n<p>Glaxo is also working with French pharmaceutical giant Sanofi on final Phase 3 tests of a different Covid vaccine, which they hope to launch by the end of this year.<\/p>\n<p>Phase 2 trials of that jab have already showed a strong immune response after a single shot in participants who had previously contracted the coronavirus.<\/p>\n<p>GSK is also working on another two separate vaccine projects, one with Canada&#8217;s Medicago and another with Germany&#8217;s CureVac.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>British drugs giant GlaxoSmithKline and South Korean peer SK bioscience have begun final stage trials of a Covid-19 jab after positive early results, they announced Tuesday. The vaccine is facing a Phase 3 clinical trial to assess its &#8220;safety and immunogenicity&#8221; when compared with AstraZeneca&#8217;s Covid vaccine, the two companies said in a joint statement. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":31990,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"spay_email":"","jetpack_publicize_message":"","jetpack_is_tweetstorm":false},"categories":[44,48],"tags":[],"jetpack_featured_media_url":"https:\/\/static.dw.com\/image\/16068964_101.jpg","jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=\/wp\/v2\/posts\/31988"}],"collection":[{"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31988"}],"version-history":[{"count":1,"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=\/wp\/v2\/posts\/31988\/revisions"}],"predecessor-version":[{"id":31989,"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=\/wp\/v2\/posts\/31988\/revisions\/31989"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=\/wp\/v2\/media\/31990"}],"wp:attachment":[{"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailyhomeland.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}